TrialsgrambetaRCTs are beautiful

MENTOR

2019

Membranous Nephropathy Trial of Rituximab

In 130 patients with membranous nephropathy at moderate-to-high risk, rituximab achieved more complete or partial remission at 24 months than cyclosporine.

Result

Complete or partial remission of proteinuria at month 24
Absolute difference
40 points
NNT
3
Effect estimate

risk difference4095% CI 25-55 · P < 0.001

Absolute difference and NNT are derived from the event rates.

Also reported: Superiority); noninferior at 12mo (60% vs 52%, P=0.004).

Original publication
Subtopic
Membranous nephropathy
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
Fervenza FC, et al. N Engl J Med. 2019;381(1):36-46.doi 10.1056/NEJMoa1814427

Discussion & critique

Established rituximab as a first-line option in KDIGO 2021; deeper and earlier anti-PLA2R decline than with cyclosporine.

Discussed in podcasts